Please assess the completion status of the following clinical trial:

Trial Title: Cord Blood Transplantation for Patients With Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed or refractory acute leukemia (myeloid or lymphoid)~* Acute leukemia in first remission at high-risk for recurrence~* Chronic myelogenous leukemia in accelerated phase or blast-crisis~* Chronic myelogenous leukemia in chronic phase~* Recurrent or refractory malignant lymphoma or Hodgkin lymphoma~* Chronic lymphocytic leukemia, relapsed or with poor prognostic features~* Multiple myeloma~* Myelodysplastic syndrome~* Chronic myeloproliferative disease~* Hemoglobinopathies~* Aplastic anemia~Exclusion Criteria:~* Zubrod performance status \> 2~* Life expectancy is severely limited by concomitant illness~* Patients with severely decreased LVEF or impaired pulmonary function tests~* Estimated Creatinine Clearance \<50 ml/min~* Serum bilirubin\> 2.0 mg/dl or SGPT \>3 x upper limit of normal~* Evidence of chronic active hepatitis or cirrhosis~* HIV-positive~* Patient is pregnant~* Patient or guardian not able to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conditioning Regimen I (Type: EXPERIMENTAL): Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)
- Conditioning Regimen II (Type: EXPERIMENTAL): Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).

Based on this trial design, predict the completion outcome and termination type (if applicable).